Recurrent Leiomyosarcoma

Recurrent leiomyosarcoma is when this aggressive cancer returns after initial treatment, presenting challenges for patients and their medical teams. Understanding recurrence patterns, treatment options, and factors that influence survival can help patients navigate this difficult journey.

Table of contents

• What Is Recurrence in Leiomyosarcoma
• How Common Is Recurrence
• Where Leiomyosarcoma Recurs
• Timing of Recurrence
• Treatment Options for Recurrent Disease
• Survival Outcomes
• Factors Affecting Prognosis
• Monitoring for Recurrence

What Is Recurrence in Leiomyosarcoma

Recurrent leiomyosarcoma means the cancer has come back after initial treatment. Leiomyosarcoma is a rare, aggressive cancer that forms in smooth muscles found in hollow organs like the bladder, stomach, uterus, intestines, and blood vessels^[2]. When this cancer returns, it can appear in the same location where it originally developed or spread to other parts of the body.

The cancer cells can travel through the bloodstream and spread to any soft tissue in the body^[2]. This makes recurrence a serious concern for patients who have completed their initial treatment.

How Common Is Recurrence

Recurrence is unfortunately common with leiomyosarcoma. Research shows that about 39% of patients with primary leiomyosarcoma experience recurrence^[1]. The rate varies depending on where the original tumor was located. Studies have found that 51% of patients with abdominal or retroperitoneal (back of the abdomen) leiomyosarcoma had recurrence, compared to 33% of patients with tumors in the arms or legs, and 26% of patients with tumors on the trunk^[1].

For uterine leiomyosarcoma specifically, the recurrence rate has been reported to be between 45% and 73%^[3]. This high rate of recurrence makes long-term follow-up essential for all patients.

Where Leiomyosarcoma Recurs

Recurrent leiomyosarcoma can appear in different locations depending on the original tumor site. Most patients with uterine leiomyosarcoma experience recurrence within the pelvis and upper abdomen. The lungs are also a common site for spread^[3].

In one study of women with recurrent uterine leiomyosarcoma, 19.2% of patients who underwent surgery had thoracic (chest) surgery because of lung-only recurrence. Bowel surgery was performed in 15.4% of patients, bladder surgery in 5.8%, and liver surgery in 1.9%^[3].

For small bowel leiomyosarcoma, recurrence can occur in the same area or spread to distant sites^[7].

Timing of Recurrence

The time between initial treatment and recurrence varies widely. For uterine leiomyosarcoma, the median interval to first recurrence is estimated to be around 12 to 24 months^[3]. However, recurrence can happen much earlier or later than this timeframe.

The chances of recurrence are highest in the first five years after treatment^[16]. Late recurrence, occurring more than five years after initial treatment, happens in about 9% of patients with abdominal or retroperitoneal leiomyosarcoma and 4% of patients with tumors in the arms or legs^[1].

The timing of recurrence is important because it can affect treatment options and outcomes. Patients who experience their first recurrence within 12 months of initial diagnosis tend to have worse survival rates than those who recur after 12 months^[3].

Treatment Options for Recurrent Disease

Treatment for recurrent leiomyosarcoma depends on several factors, including previous therapy, the location of the recurrent tumor, time to recurrence, and the patient’s overall health^[3].

Surgery

Surgery is an important treatment option for recurrent leiomyosarcoma and can provide an opportunity for long-term survival in carefully selected patients^[3]. The best candidates for surgery are patients who have a prolonged time between their initial treatment and recurrence, and who have a single site of recurrence that can be completely removed^[3].

Secondary cytoreductive surgery (surgery to remove as much of the recurrent tumor as possible) can be beneficial when doctors can achieve complete removal with no remaining disease^[3]. In one study, 73.2% of patients with recurrent uterine leiomyosarcoma received this type of surgery, and complete removal was achieved in 90.4% of these cases^[3].

In some cases, surgery may involve removing parts of organs that are not reproductive organs. This can include surgery on the lungs, bowels, bladder, or liver, depending on where the cancer has spread^[3].

Systemic Therapy

Systemic therapies, including chemotherapy and targeted therapies, play a role in treating recurrent leiomyosarcoma. These treatments are especially important when surgery is not possible or when the cancer has spread to multiple sites^[5].

Leiomyosarcoma is relatively resistant to chemotherapy and radiation therapy^[3]. However, new treatment options have been approved in recent years, expanding the choices available to patients^[5]. The challenge for doctors is selecting and properly sequencing these treatments.

Multimodal Approach

A combination of different treatment methods may provide the best outcomes. One case report described a patient with recurrent uterine leiomyosarcoma that had spread to the spine who was treated with surgery, radiosurgery, and chemotherapy. This multimodal approach kept the patient progression-free for 35 months^[11].

Modern multimodal therapy, combining chemotherapy with aggressive surgery in selected patients, may be significant in prolonging survival for women with this disease^[3].

Survival Outcomes

The prognosis for patients with recurrent leiomyosarcoma is generally poor. The five-year survival rate after relapse has been reported as 15%^[3]. Very few patients with recurrent or metastatic (spread to other parts of the body) leiomyosarcoma can be cured^[3].

However, survival outcomes can vary considerably based on individual circumstances. In one study of women with recurrent uterine leiomyosarcoma, the five-year overall survival for the entire group was 52.9%^[3]. Patients who received secondary cytoreductive surgery had a five-year survival rate of 62.0%, compared to 28.0% for those who did not have surgery^[3].

Factors Affecting Prognosis

Several factors influence the prognosis for patients with recurrent leiomyosarcoma.

Time to First Recurrence

The time between initial diagnosis and first recurrence is a significant predictor of survival. Patients who experience their first recurrence within 12 months of initial diagnosis have much worse outcomes than those who recur after 12 months. In one study, the five-year survival rate was 17.0% for those recurring within 12 months compared to 69.1% for those recurring after 12 months^[3].

For patients undergoing secondary surgery, time to first recurrence within 12 months was identified as an independent predictor of decreased five-year survival^[3].

Tumor Characteristics

In primary leiomyosarcoma, both tumor grade (how abnormal the cells look under a microscope) and size are significant independent predictors of survival and distant recurrence^[1]. High-grade tumors and larger tumors are associated with worse outcomes.

For local recurrence, significant independent predictors are tumor size and surgical margins (whether all of the tumor was removed)^[1].

Completeness of Surgery

When surgery is performed for recurrent disease, achieving complete removal with no remaining tumor is crucial. Complete resection provides the best chance for long-term survival^[3].

Monitoring for Recurrence

Regular follow-up care is essential for detecting recurrence early. Because recurrence is most common in the first five years after treatment, frequent monitoring is especially important during this period^[16].

Follow-up appointments are typically scheduled every three to six months for the first two to three years after treatment ends, then every six months for the next two years. After five years, annual visits are recommended for life^[16].

During these visits, doctors will perform physical examinations and may order imaging tests such as CT scans, MRI scans, ultrasounds, or chest X-rays. These tests look for signs of cancer returning in the area where it started or spreading to other parts of the body like the lungs^[16].

Patients should immediately report any new symptoms to their doctor, including new lumps, swollen areas, tenderness, pain, unusual vaginal bleeding or discharge, or changes in bladder or bowel habits^[16].